Mobile

A Randomized, Open-Label, Multicenter Study Examining the Effects of 24 Versus 48 Weeks of Combination Therapy with PEGASYS® (Peginterferon alfa-2a 40KD) plus COPEGUS® (Ribavirin) on Sustained Virol...

Mise à jour : Il y a 5 ans
Référence : EUCTR2007-004993-15

A Randomized, Open-Label, Multicenter Study Examining the Effects of 24 Versus 48 Weeks of Combination Therapy with PEGASYS® (Peginterferon alfa-2a 40KD) plus COPEGUS® (Ribavirin) on Sustained Virological Response in Patients with Chronic Hepatitis C, Genotype 2 or 3 who do not Achieve a Rapid Viral Response

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To evaluate the effect of PEGASYS® (peginterferon alfa-2a 40KD) plus COPEGUS® (ribavirin) combination therapy given for 24 weeks versus 48 weeks on the clearance of HCV viremia 24 weeks after treatment end (sustained virological response, SVR) in patients with chronic hepatitis C (CHC) virus infection and Genotype 2/3, who do not achieve a rapid viral response (RVR, defined as undetectable HCV RNA by the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test ) at week 4 but have an early virological response at week 12 (EVR, defined as undetectable HCV RNA or a drop of ≥2-log10)

Critère d'inclusion

  • Chronic hepatitis C

Liens